Skip to main content
. 2015 Oct 7;8:546. doi: 10.1186/s13104-015-1507-z

Table 2.

Comparison of the in vitro biological potency of the amikacin products studied

Product Escherichia coli SIG-1 Pseudomonas aeruginosa ATCC 27853
MIC Min Max MBC Min Max MIC Min Max MBC Min Max
BMS 1.59 1.00 2.00 1.78 1.00 2.00 4.00 4.00 4.00 10.08 8.00 16.00
Carlon 4.00 4.00 4.00 8.00 8.00 8.00 5.66 4.00 8.00 5.66 4.00 8.00
FormasG 4.00 4.00 4.00 4.00 4.00 4.00 5.66 4.00 8.00 8.00 8.00 8.00
Gencol 2.00 2.00 2.00 2.00 2.00 2.00 4.00 4.00 4.00 8.00 4.00 16.00
Genven 2.00 2.00 2.00 2.00 2.00 2.00 2.83 2.00 4.00 5.66 4.00 8.00
Pisa 2.00 2.00 2.00 2.83 2.00 4.00 4.00 4.00 4.00 11.31 8.00 16.00
Quimicol 2.83 1.00 8.00 4.00 2.00 8.00 3.36 2.00 4.00 6.73 4.00 16.00
Scalpi 2.83 2.00 4.00 2.83 2.00 4.00 4.00 4.00 4.00 4.00 4.00 4.00
Serpharma** 19.03 16.00 32.00 22.63 16.00 32.00 38.05 32.00 64.00 64.00 64.00 64.00
Sigma 1.41 1.00 2.00 2.83 2.00 4.00 4.00 4.00 4.00 8.00 8.00 8.00
Zokumey 2.00 2.00 2.00 4.00 2.00 8.00 4.00 4.00 4.00 11.31 8.00 16.00

Concentrations are expressed as geometric mean and range (Min. and Max) in mg/L

MIC minimal inhibitory concentration, MBC minimal bactericidal concentration

** p value <0.05 by Dunn’s multiple comparison test